Free tool
FAERS Monitor: Kisunla
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761248 or its brand name (Kisunla, Donanemab-Azbt). Reports on generic versions are filed under their own applications.
Reports
3,074
Serious
1,485
48% of reports
Hospitalization
382
Death reported
71
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- amyloid related imaging abnormality-oedema/effusion503
- amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits416
- infusion related reaction390
- headache276
- flushing196
- amyloid related imaging abnormalities181
- nausea140
- cerebral haemorrhage130
- dizziness129
- cerebral microhaemorrhage109
- chills105
- dyspnoea105
- confusional state93
- back pain83
- fall79
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 74 |
| 2025 | 1,440 |
| 2026 | 1,560 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,085 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amyloid related imaging abnormalitiesSignal | 181 | 9047.5 | 7267.2 | 701,468 |
| amyloid related imaging abnormality-oedema/effusionSignal | 503 | 4738.1 | 4252.9 | 1,405,333 |
| amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsSignal | 416 | 4336.1 | 3855.0 | 1,101,373 |
| cerebral microhaemorrhageSignal | 109 | 2163.6 | 1749.5 | 177,411 |
| infusion related reactionSignal | 390 | 40.5 | 36.9 | 14,940 |
| cerebral haemorrhageSignal | 130 | 24.9 | 21.1 | 2,957 |
| flushingSignal | 196 | 13.2 | 11.5 | 2,207 |
| chillsSignal | 105 | 6.1 | 5.1 | 448 |
| confusional stateSignal | 93 | 3.9 | 3.2 | 203 |
| headacheSignal | 276 | 3.0 | 2.7 | 380 |
| back painSignal | 83 | 2.4 | 2.0 | 70 |
| dizziness | 129 | 1.8 | 1.5 | 43 |
| fall | 79 | 1.6 | 1.3 | 19 |
| dyspnoea | 105 | 1.3 | 1.1 | 6 |
| nausea | 140 | 1.2 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.